Atherosclerosis Treatment Drugs Market

Atherosclerosis Treatment Drugs Market with Major Provincial
Sectors, key players such as GlaxoSmithKline plc. Merck & Co.,
Inc., F. Hoffmann-La Roche Ltd., Isis Pharmaceuticals, Inc.
Atherosclerosis is characterized by the narrowing and hardening of the arteries. In this
condition, arteries become blocked by fatty substances, such as cholesterol. These substances are
called as plaques or atheroma. The risks of atherosclerosis increase with age. The deposition of
plaque tends to narrow the arterial canal, which result in the limited flow of blood and oxygen
through it. Atherosclerosis commences with damage to the endothelium of arteries leading to
the formation of plaque. This condition is dangerous for the vital organs such as heart and
brain. The risk associated with atherosclerosis includes serious cardiovascular and brain diseases.
Collectively, these conditions are more common for cardiovascular diseases (CVD) including
coronary heart disease, angina pectoris, and transitory ischemia. Other risks for atherosclerosis
are carotid artery disease, kidney disease, and peripheral artery disease.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/2430
Atherosclerosis Treatment Drugs Market – Driver
Increasing number of pipeline studies and rising involvement of key players for developing the
treatment options for atherosclerosis are expected to propel atherosclerosis treatment drugs
market growth. For Instance, in November 13, 2018, Bayer in collaboration with Janssen, LP
started the clinical study for Rivaroxaban and Acetylsalicylic Acid to build up the insights in
treatment patterns and to study results of Rivaroxaban (Xarelto) in combination with
acetylsalicylic acid (xatoa) prescribed to patients with atherosclerosis. The study is estimated to
complete in August 2021.
Moreover, technological advancement in the atherosclerosis treatment procedures is expected to
boost the atherosclerosis treatments drug market growth. For instance, in May 2017,
Researchers at Ben-Gurion University (BGU) and the Sheba Medical Center developed Nano
polymer therapy, a new therapy for the treatment of atherosclerosis. It prevents heart failure
with a new biomedical polymer (E-selectin-targeting polymer) that reduces arterial plaque and
inflammation in the cardiovascular system. E-selectin-targeting polymer helps to reduce existing
plaque and impedes the further plaque formation. It also prevents arterial thrombosis, ischemia,
myocardial infarction, and strokes.
Report includes chapters which deeply display the following deliverable about industry :
• Atherosclerosis Treatment Drugs Market Research Objective and Assumption
• Atherosclerosis Treatment Drugs Market Purview - Report Description, Executive Summary,
and Coherent Opportunity Map (COM)
• Atherosclerosis Treatment Drugs Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Atherosclerosis Treatment Drugs Market, By Regions
• Atherosclerosis Treatment Drugs Market Competition by Manufacturers including Production,
Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Atherosclerosis Treatment Drugs Market Manufacturers Profiles/Analysis including Company
Basic Information, Manufacturing Base and Its Competitors.
• Atherosclerosis Treatment Drugs Market Manufacturing Cost Analysis including Key Raw
Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Atherosclerosis Treatment Drugs Market Forecast including Production, Consumption, Import
and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Atherosclerosis Treatment Drugs Market- Restraints
However, the side effects associated with atherosclerosis drugs and limited efficacy of the drugs
is expected to hamper atherosclerosis market growth. For instance, in November 2016, The
Lancet led by Rory Collins, provided an evidence on statin therapy and the methodological
limitations. As per data, statins are associated with increased incidence of diabetes and
hemorrhagic stroke. Statins tends to increase the risk of type 2 diabetes in a dose-dependent
mode.
Atherosclerosis Treatment Drugs Market- Regional Analysis
On the basis of region, the global atherosclerosis treatment drugs market is segmented into
North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Geographically, North America is expected to gain significant market share over the forecast
period, owing to increasing incidences of atherosclerotic condition among the population in this
region. For instance, in November 2016, as per data provided by the U.S. Centers for Disease
Control and Prevention (CDC) and the World Health Organization (WHO), there were more than
15.5 million Americans who had coronary artery disease and it is expected that for every 42
seconds an American will experience the onset of a myocardial infarction.
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/2430
Furthermore, Asia Pacific is expected to witness significant growth in the market, owing to
expansion of major key players in this region. For instance, in October 2017, GSK opened its
new regional headquarters for Asia in Singapore. The GSK’s purpose for building headquarters
is to support the pharmaceutical, vaccines, and consumer healthcare businesses across multiple
regions in Asia Pacific.
Key players operating in the Atherosclerosis treatment drugs market include GlaxoSmithKline
plc. Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Isis Pharmaceuticals, Inc., Anthera
Pharmaceuticals, Novartis AG, Sanofi, Johnson and Johnson, Bayer AG, The Medicine Company,
and Cardium Therapeutics.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Atherosclerosis is characterized by the narrowing and hardening of the arteries. In this condition, arteries become blocked by fatty substances, such as cholesterol.

Download Report